Announcements Trials
Browse Landscape

Phase

Phase 2 67Phase 1/2 9Phase NA 5Phase 4 3Phase 3 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 2Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Genitourinary 1

Conditions

Colorectal Neoplasms 3Stomach Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Exercise 419Blood Specimen Collection 319Standard of Care 299Surveys and Questionnaires 242Radiosurgery 239Magnetic Resonance Spectroscopy 232Educational Status 223Methods 221Radiotherapy 216Early Intervention, Educational 200Interviews as Topic 142Practice Guidelines as Topic 141Biopsy 125Surgical Procedures, Operative 119Drug Therapy 119Acupuncture Therapy 119Control Groups 115Therapeutics 101Palliative Care 97Resistance Training 94Counseling 88Saline Solution 87Magnetic Resonance Imaging 84Cyclophosphamide 83Specimen Handling 73Cisplatin 73Radiofrequency Ablation 71Cognitive Behavioral Therapy 71Radiotherapy, Intensity-Modulated 68Colonoscopy 65

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase NA × OTHER × HMPL-013 × Clear all
NCT07124858 2026-05-26

COFRUQ

Federation Francophone de Cancerologie Digestive

Phase NA Recruiting
300 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT07552402 2026-04-27

FREEDOM

Harbin Medical University

Phase NA Not yet recruiting
150 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06985316 2025-05-22

An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

Tongji Hospital

Phase NA Not yet recruiting
34 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06551207 2024-08-13

Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC

Tongji Hospital

Phase NA Recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06317298 2024-03-19

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Peking University First Hospital

Phase NA Unknown
36 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡